Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a lethal progressive lung disease urgently needing new therapies. Current treatments only delay disease progression, leaving lung transplant as the sole remaining option. Recent studies support a model whereby IPF arises because alveolar epithelial type II (AT2) cells, which normally mediate distal lung regeneration, acquire airway and/or mesenchymal characteristics, preventing proper repair. Mechanisms driving this abnormal differentiation remain unclear. We performed integrated transcriptomic and epigenomic analysis of purified AT2 cells which revealed genome-wide alterations in IPF lungs. The most prominent epigenetic alteration was activation of an enhancer in thyroid receptor interactor 13 (TRIP13), although TRIP13 was not the most significantly transcriptionally upregulated gene. TRIP13 is broadly implicated in epithelial-mesenchymal plasticity. In cultured human AT2 cells and lung slices, small molecule TRIP13 inhibitor DCZ0415 prevented acquisition of the mesenchymal gene signature characteristic of IPF, suggesting TRIP13 inhibition as a potential therapeutic approach to fibrotic disease.

Authors

Institutions

Publication Details

Journal
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Published
2024-11-13
DOI
https://doi.org/10.1016/j.bbadis.2024.167572
Citations
2
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.84

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis

Asres Berhan, Angela Meier, Kamyar Afshar, Amy L. Ryan et al.
2 citations
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
0.84
article

Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis

Asres Berhan, Angela Meier, Kamyar Afshar, Amy L. Ryan, Ite A. Laird‐Offringa, Haoze Yu, Zea Borok, Alessandra Castaldi, Eugene Golts, Crystal N. Marconett, Grace Lin, Laurence St. Pierre, Hongjun Wang, Yixin Liu, Beiyun Zhou, Juan R. Alvarez, Eun Kyu Sung, Yanbin Ji, Ben A. Calvert
article en
2 citations

Abstract

Idiopathic pulmonary fibrosis (IPF) is a lethal progressive lung disease urgently needing new therapies. Current treatments only delay disease progression, leaving lung transplant as the sole remaining option. Recent studies support a model whereby IPF arises because alveolar epithelial type II (AT2) cells, which normally mediate distal lung regeneration, acquire airway and/or mesenchymal characteristics, preventing proper repair. Mechanisms driving this abnormal differentiation remain unclear. We performed integrated transcriptomic and epigenomic analysis of purified AT2 cells which revealed genome-wide alterations in IPF lungs. The most prominent epigenetic alteration was activation of an enhancer in thyroid receptor interactor 13 (TRIP13), although TRIP13 was not the most significantly transcriptionally upregulated gene. TRIP13 is broadly implicated in epithelial-mesenchymal plasticity. In cultured human AT2 cells and lung slices, small molecule TRIP13 inhibitor DCZ0415 prevented acquisition of the mesenchymal gene signature characteristic of IPF, suggesting TRIP13 inhibition as a potential therapeutic approach to fibrotic disease.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseVol. 1871(3)
University of Southern California (US), University of Iowa (US), University of California San Diego (US), Southern California Clinical and Translational Science Institute (US)
Pulmonary Fibrosis Foundation, Tobacco-Related Disease Research Program, Cystic Fibrosis Foundation Therapeutics, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute
Zero hunger
Openalex Percentile: Top 23%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
0.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.